Intragenic ERBB2 kinase mutations in tumours

Cited by (802)

Items 401–500 of 802

1. Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
   Masayuki Takeda, Kazuko Sakai, Hidetoshi Hayashi, Kaoru Tanaka, Junko Tanizaki, Takayuki Takahama, Koji Haratani, Kazuto Nishio, Kazuhiko Nakagawa · 2018 · Oncotarget
2. HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities
   Ahmed Ismail, Aakash P. Desai, Yanis Boumber · 2025 · Frontiers in Oncology
3. Apoptosis block as a barrier to effective therapy in non small cell lung cancer
   Ian Paul · 2014 · World Journal of Clinical Oncology
4. Braf and erbB2 mutations correlate with smoking status in lung cancer patients
   Hidefumi Sasaki, Masayuki Shitara, Keisuke Yokota, Katsuhiro Okuda, Yu Hikosaka, Satoru Moriyama, Motoki Yano, Yoshitaka Fujii · 2012 · Experimental and Therapeutic Medicine
5. ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty
   Richard J. Gilbertson · 2005 · The Oncologist
6. Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires
   Conant, Genevieve, Ahadian, Samad, Zhao, Yimu, Radisic, Milica · 2017 · Scientific Reports
7. Molecular Pathology of Lung Cancer
   Luisa Maren Solis, Ignacio Ivan Wistuba · 2012 · Springer eBooks
8. Systemic and Targeted Therapies for Early-Stage Lung Cancer
   Elizabeth Byron, Mary C. Pinder-Schenck · 2014 · Cancer Control
9. Cancer Etiology and Prevention Principle: “1 + X”
   Hui Liu, Zigang Dong · 2021 · Cancer Research
10. IGDB.NSCLC: integrated genomic database of non-small cell lung cancer
    Senyeong Kao, Cheng-Kai Shiau, De-Leung Gu, Chun‐Ming Ho, Wen-Hui Su, Chian‐Feng Chen, Chi‐Hung Lin, Yuh‐Shan Jou · 2011 · Nucleic Acids Research
11. Cell-free expression of functional receptor tyrosine kinases
    Wei He, Tiffany M. Scharadin, Matthew Saldana, Candice A. Gellner, Steven A. Hoang-Phou, Christina L. Takanishi, Greg L. Hura, John A. Tainer, Kermit L. Carraway, Paul T. Henderson et al. · 2015 · Scientific Reports
12. Unlocking the future of cancer diagnosis – promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer
    Chiara Reina, Berina Šabanović, Chiara Lazzari, Vanesa Gregorc, Christopher Heeschen · 2024 · Translational research
13. Rare Mutations in Non-Small-Cell Lung Cancer
    Manolo D’Arcangelo, Armida D’Incecco, Federico Cappuzzo · 2013 · Future Oncology
14. Biophysical simulations and structure-based modeling of residue interaction networks in the tumor suppressor proteins reveal functional role of cancer mutation hotspots in molecular communication
    Gennady M. Verkhivker · 2018 · Biochimica et Biophysica Acta (BBA) - General Subjects
15. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
    Xuefei Li, Chao Zhao, Chunxia Su, Shengxiang Ren, Xiaoxia Chen, Caicun Zhou · 2016 · BMC Cancer
16. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression
    Zhang Li, Chenghao Shao, Xiaoxiao Liu, Xiaojing Lu, Xiaona Jia, Xufen Zheng, Simin Wang, Li Zhu, Ke Li, Yuzhi Pang et al. · 2019 · Carcinogenesis
17. Molecular Pathogenesis of Early-Stage Non-small Cell Lung Cancer and a Proposal for Tissue Banking to Facilitate Identification of New Biomarkers
    Maria Gabriela Raso, Ignacio Ivan Wistuba · 2007 · Journal of Thoracic Oncology
18. Targeting HER1/EGFR in Cancer Therapy: Experience with Erlotinib
    Giuseppe Giaccone · 2005 · Future Oncology
19. Therapeutic strategies for afatinib‐resistant lung cancer harboring HER 2 alterations
    Hidejiro Torigoe, Kazuhiko Shien, Tatsuaki Takeda, Takahiro Yoshioka, Kei Namba, Hiroki Sato, Ken Suzawa, Hiromasa Yamamoto, Junichi Soh, Masakiyo Sakaguchi et al. · 2018 · Cancer Science
20. Mechanisms of Disease: signal transduction in lung carcinogenesis—a comparison of smokers and never-smokers
    Giannis Mountzios, Pierre Jean Fouret, Jean‐Charles Soria · 2008 · Nature Clinical Practice Oncology
21. Iressa induces cytostasis and augments Fas‐mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu
    Marie P. Piechocki, George H. Yoo, Susan K. Dibbley, Esmael H. Amjad, Fulvio Lonardo · 2006 · International Journal of Cancer
22. Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
    Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas, Daniel Korr, Haruna Tomono, Sawyer Andersen, D.R. Denney, Markus Berger, Volker Schulze et al. · 2025 · Cancer Discovery
23. Expression of NRG1 and its receptors in human bladder cancer
    J A Forster, Alan Paul, Patricia Harnden, Margaret A. Knowles · 2011 · British Journal of Cancer
24. SGK3 is associated with estrogen receptor expression in breast cancer
    Jun Qiang Xu, Ma Wan, Quanyuan He, Roland L. Bassett, Xiaoyong Fu, Albert C. Chen, Feng-Tao Shi, Chad J. Creighton, Rachel Schiff, Lei Huo et al. · 2012 · Breast Cancer Research and Treatment
25. Therapeutic targeting of receptor tyrosine kinases in lung cancer
    Nicholas W. Choong, Patrick C Ma, Ravi Salgia · 2005 · Expert Opinion on Therapeutic Targets
26. Lung cancers unrelated to smoking: characterized by single oncogene addiction?
    Kenichi Suda, Kenji Tomizawa, Yasushi Yatabe, Tetsuya Mitsudomi · 2011 · International Journal of Clinical Oncology
27. ERBB2 kinase domain mutation in a gastric cancer metastasis
    Jong Woo Lee, Young Hwa Soung, Su Young Kim, Won Sang Park, Suk Woo Nam, Sang Ho Kim, Jung Young Lee, Nam Jin Yoo, Sug Hyung Lee · 2005 · Apmis
28. A Curious Link Between Epidermal Growth Factor Receptor Amplification and Survival: Effect of “Allele Dilution” on Gefitinib Sensitivity?
    Frederic J. Kaye · 2005 · JNCI Journal of the National Cancer Institute
29. Emerging Targets in Advanced Non-Small-Cell Lung Cancer
    Francesco Valentino, Gloria Borra, Paolo Allione, Lorena Rossi · 2018 · Future Oncology
30. siRNA Targeting against EGFR, a Promising Candidate for a Novel Therapeutic Application to Lung Adenocarcinoma
    Sumitaka Yamanaka, Zhaodi Gu, Masami Sato, Rumi Fujisaki, Kenichi Inomata, Akira Sakurada, Akira Inoue, Toshihiro Nukiwa, Takashi Kondo, Akira Horii · 2008 · Pathobiology
31. HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top
    Pamela Trillo Aliaga, Gianluca Spitaleri, Ilaria Attili, Carla Corvaja, Elena Battaiotto, Panagiotis Agisilaos Angelopoulos, Ester Del Signore, Antonio Passaro, Filippo de Marinis · 2025 · Molecules
32. Cryptic amyloidogenic regions in intrinsically disordered proteins: Function and disease association
    Jaime Santos, Irantzu Pallarès, Valentín Iglesias, Salvador Ventura · 2021 · Computational and Structural Biotechnology Journal
33. Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases
    Andrew Shih, Shannon Telesco, Ravi Radhakrishnan · 2011 · Cancers
34. Molecular determinants of lung cancer metastasis to the central nervous system.
    Timothy G. Whitsett, Landon J. Inge, Harshil Dhruv, Philip Yue-Cheng Cheung, Glen J. Weiss, Ross Macrae Bremner, Jeffrey A. Winkles, Nhan L. Tran · 2013 · Europe PMC (PubMed Central)
35. Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4
    Amy J. Jackson-Fisher, Gary Bellinger, Elaine Shum, Janna K. Duong, Archibald S. Perkins, Martin Gassmann, William J. Muller, K. C. Kent Lloyd, D F Stern · 2006 · Oncogene
36. Targeted Therapies in Combination with Chemotherapy in Non–Small Cell Lung Cancer
    David H. Johnson · 2006 · Clinical Cancer Research
37. Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases
    Yanjun Xu, Zhiyu Huang, Xiaoqing Yu, Kaiyan Chen, Yun Fan · 2021 · Molecular Brain
38. Adenocarcinoma, a molecular perspective
    Rolf A. Stahel · 2007 · Annals of Oncology
39. Diagnostic and Predictive Immunohistochemistry for Non–Small Cell Lung Carcinomas
    Yin Pun Hung, Lynette Marie Sholl · 2018 · Advances in Anatomic Pathology
40. Anti‑tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
    Yusuke Ogoshi, Kazuhiko Shien, Takahiro Yoshioka, Hidejiro Torigoe, Hiroki Sato, Masakiyo Sakaguchi, Shuta Tomida, Kei Namba, Eisuke Kurihara, Yuta Takahashi et al. · 2019 · Oncology Letters
41. Targeting HER2 Epitopes.
    S. Pal, M. Pegram · 2006 · Seminars in Oncology
42. Machine Learning Classification and Structure–Functional Analysis of Cancer Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes
    Steve Agajanian, Oluyemi Odeyemi, Nathaniel Bischoff, Simrath Ratra, Gennady M. Verkhivker · 2018 · Journal of Chemical Information and Modeling
43. Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer
    Marjut Puputti, Harri J. Sihto, Jorma J Isola, Ralf C. Bützow, Heikki Joensuu, Nina N. Nupponen · 2006 · Cancer Genetics and Cytogenetics
44. Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients
    Marianna Scrima, Federica Zito Marino, Duarte Mendes Oliveira, Cinzia Marinaro, Elvira La Mantia, Gaetano Rocco, Carmela De Marco, Donatella Malanga, Nicla De Rosa, Antonia Rizzuto et al. · 2017 · Journal of Cancer
45. Exploratory analysis of introducing next-generation sequencing-based method to treatment-naive lung cancer patients
    written on behalf of the AME Lung Cancer Collaborative Group, Yufang Feng, Gaohua Feng, Xiaoling Lu, Wenxia Qian, Junyi Ye, Carmen Areses Manrique, Chunping Ma, Yadong Lu · 2018 · Journal of Thoracic Disease
46. HER4 promotes the growth and metastasis of osteosarcoma via the PI3K/AKT pathway
    Xiaodong Li, Qingshan Huang, Shenglin Wang, Zhen Huang, Fengqiang Yu, Jianhua Lin · 2020 · Acta Biochimica et Biophysica Sinica
47. Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia
    Yuki Kato, Hibiki Udagawa, Shingo Matsumoto, Hiroki Izumi, Yuichiro Ohe, Terufumi Kato, Kazumi Nishino, Shingo Miyamoto, Sachiko Kawana, Kenichi Chikamori et al. · 2024 · Lung Cancer
48. Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma
    Farzaneh Kordbacheh, Camile Selim Farah · 2021 · Cancers
49. Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study
    Xiangling Chu, Huiping Qiang, Mengqing Xie, Xing Li, Jing Zhao, Yan Wu, Juan Zhou, Jinyan Ye, Chao Zhao, Chaonan Han et al. · 2021 · Cancer Immunology Immunotherapy
50. HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
    Ioannis Athanasios Vathiotis, Andriani G. Charpidou, Niki Gavrielatou, Konstantinos Nikolaos Syrigos · 2021 · Pharmaceuticals
51. miR‐221 confers lapatinib resistance by negatively regulating p27kip1 in HER2‐positive breast cancer
    Thanh Kieu Huynh, Chih‐Hao Huang, Jhen‐Yu Chen, J. Yao, Yi‐Shiang Yang, Ya‐Ling Wei, Hsiao‐Fan Chen, Chia‐Hung Chen, Chih‐Yen Tu, Yuan‐Man Hsu et al. · 2021 · Cancer Science
52. Targeting the Calmodulin-Regulated ErbB/Grb7 Signaling Axis in Cancer Therapy
    Antonio Villalobo, Irene García‐Palmero, Silviya R. Stateva, Karim Jellali · 2013 · Journal of Pharmacy & Pharmaceutical Sciences
53. Accurate calculation of mutational effects on the thermodynamics of inhibitor binding to p38α MAP kinase: a combined computational and experimental study
    Shun Zhu, S. Travis, A. Elcock · 2013 · Journal of Chemical Theory and Computation
54. Lung cancer biology: a genetic and genomic perspective
    Montse Sánchez‐Céspedes · 2009 · Clinical & Translational Oncology
55. Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer
    Finn Edler von Eyben · 2006 · Critical Reviews in Clinical Laboratory Sciences
56. The paradigm of personalized therapy in oncology
    Giampietro Gasparini, Raffaele Longo · 2011 · Expert Opinion on Therapeutic Targets
57. Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field
    Anna‐Lena Volckmar, Petros Christopoulos, Martina Kirchner, Michael Allgäuer, Olaf Neumann, Jan Budczies, Eugen Rempel, Peter Horak, Julia Glade, Hannah Goldschmid et al. · 2021 · Lung Cancer
58. Chinese expert consensus on the diagnosis and treatment of HER2 ‐altered non–small cell lung cancer
    Shirong Zhang, Wenxian Wang, C. Xu, Yongchang Zhang, Xiuyu Cai, Qian Wang, Zhengbo Song, Ziming Li, Jinpu Yu, Wen‐Zhao Zhong et al. · 2022 · Thoracic Cancer
59. MET inhibition in lung cancer.
    Jessica Menis, Matteo Giaj Levra, Silvia Novello · 2013 · Europe PMC (PubMed Central)
60. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study
    Bei Yang, Haiping Zhang, Hao Wang · 2015 · Journal of Molecular Modeling
61. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients
    Sangeet Bhaumik, Firoz Ahmad, Bibhu Ranjan Das · 2016 · Medical Oncology
62. Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
    Bin-Chi Liao, Chia‐Chi Lin, James Chih‐Hsin Yang · 2017 · Current Oncology Reports
63. Targeted Therapies in Non-small-Cell Lung Cancer
    Addie Hill, Rohan V. Gupta, Dan Zhao, Ritika Vankina, Idoroenyi Usua Amanam, Ravi Salgia · 2019 · Cancer treatment and research
64. Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer
    Marie‐Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaría · 2020 · Trends in cancer
65. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments
    Joshua E. Reuss, Laura Gosa, Stephen V. Liu · 2021 · Clinical Lung Cancer
66. Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report
    Fengting Yan, Kristine J. Rinn, Jonathon A. Kullnat, Aimee Wu, Maura D. Ennett, Elizabeth L. Scott, Henry G. Kaplan · 2022 · Journal of the National Comprehensive Cancer Network
67. Mechanisms of lung cancer
    Евгений Наумович Имянитов, Ekatherina Sh. Kuligina, Евгения Витальевна Белогубова, Alexandr V. Togo, Kaido P. Hanson · 2005 · Drug Discovery Today Disease Mechanisms
68. The epidermal growth factor system of ligands and receptors in cancer
    William John Gullick · 2009 · European Journal of Cancer
69. ErbB Receptor Negative Regulatory Mechanisms: Implications in Cancer
    Colleen A. Sweeney, Jamie K. Miller, David L. Shattuck, Kermit L. Carraway · 2006 · Journal of Mammary Gland Biology and Neoplasia
70. Molecular determinants of response to RTK‐targeting agents in nonsmall cell lung cancer
    Niels Reinmuth, Michael A. Meister, Thomas Muley, Martin B. Steins, Michael Kreuter, Felix J.F. Herth, Hans Hoffmann, Hendrik Dienemann, Michael Thomas · 2006 · International Journal of Cancer
71. Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression
    Rudolf Götz · 2008 · Cancer Cell International
72. Emerging Biomarkers in Personalized Therapy of Lung Cancer
    Philip T. Cagle, Kirtee Raparia, Bryce Patrick Portier · 2015 · Advances in experimental medicine and biology
73. Lung cancer in never smokers: a different disease
    Tiziana Vavalà, Matteo Giaj Levra, Silvia Novello · 2014 · Current Respiratory Care Reports
74. The role of neratinib in HER2-driven breast cancer
    Mathew Amprayil Cherian, Cynthia X. Ma · 2017 · Future Oncology
75. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion
    Shang‐Gin Wu, Yi‐Nan Liu, Chong‐Jen Yu, James Chih‐Hsin Yang, Jin‐Yuan Shih · 2018 · Genes Chromosomes and Cancer
76. Somatic mutations of the HER2 in metastatic breast cancer
    Yi Fang, Yanxia Jiang, Xin Wang, Xue Wen Yang, Yinqi Gao, Jing Wang · 2014 · Tumor Biology
77. Successful treatment of a patient with Li–Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib
    Yuxia Jia, Siraj Mahamed Ali, Shumaila Saad, Courtney A Chan, Vincent A. Miller, Balázs Halmos · 2014 · Cancer Biology & Therapy
78. KRAS mutational testing in the selection of patients for EGFR-targeted therapies
    Joaquín J. García, Gregory J. Riely, Khédoudja Nafa, Marc Ladanyi · 2008 · Seminars in Diagnostic Pathology
79. Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma
    Seongmin Choi, Hyeong Ryul Kim, Chang Ohk Sung, Jongkyu Kim, Sukjun Kim, Sung‐Min Ahn, Chang‐Min Choi, Sung‐Min Chun, Eun Kyung Choi, Sang‐We Kim et al. · 2014 · Clinical Cancer Research
80. Association of EGFR and HER2 Polymorphisms with Risk and Clinical Features of Thyroid Cancer
    Maha Rebaï, Imen Kallel, Fatma Hamza, Salma Charfeddine, R Kaffel, Fadhel Guermazi, Ahmed Rebaï · 2009 · Genetic Testing and Molecular Biomarkers
81. Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
    Tae‐You Kim, Sae‐Won Han, Yung‐Jue Bang · 2007 · Expert Review of Molecular Diagnostics
82. Tailor-Made Chemotherapy For Non-Small Cell Lung Cancer Patients
    Cheng‐long Huang, Hiroyasu Yokomise, Masakazu Fukushima, Moritoshi Kinoshita · 2006 · Future Oncology
83. Emerging Options for the Management of Non-Small Cell Lung Cancer
    Daniel Binder, Karin Hegenbarth · 2013 · Clinical Medicine Insights Oncology
84. The (non)malignancy of cancerous amino acidic substitutions
    David Talavera, Martin S. Taylor, Janet M. Thornton · 2009 · Proteins Structure Function and Bioinformatics
85. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas
    Henning Reis, Tobias Herold, Saskia C. Ting, Karl Worm, U Huber, Daniel Christian Christoph, Wilfried Eberhardt, Karina Kostbade, Stefan Kasper, Georgios Stamatis et al. · 2015 · Lung Cancer
86. Impact of biomarkers on non-small cell lung cancer treatment
    Luca Toschi, Federico Cappuzzo · 2010 · Targeted Oncology
87. Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
    Àlvaro Quintanal-Villalonga, Luis G Paz-Ares, Irene Ferrer, Sonia Molina‐Pinelo · 2016 · Disease Markers
88. Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients
    Lei‐Yun Wang, Jiajia Cui, Ao-Xiang Guo, Ji‐Ye Yin · 2018 · OncoTargets and Therapy
89. Key Signaling Pathways and Targets in Lung Cancer Therapy
    Nicholas W. Choong, Ravi Salgia, Everett E. Vokes · 2007 · Clinical Lung Cancer
90. From man to mouse and back again: advances in defining tumor AKTivities in vivo
    David F. Restuccia, Brian A. Hemmings · 2010 · Disease Models & Mechanisms
91. Cardio-oncology Related to Heart Failure
    Benjamin B. Kenigsberg, Varun Jain, Ana Barac · 2017 · Heart Failure Clinics
92. A harmonized meta-knowledgebase of clinical interpretations of cancer genomic variants
    Alex Handler Wagner, Brian Walsh, Georgia Mayfield, David Tamborero, Dmitriy Sonkin, Kilannin Krysiak, Jordi Déu Pons, Ryan P. Duren, Jianjiong Gao, Julie A. McMurry et al. · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
93. Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment
    N. Anderle, Felix Schäfer-Ruoff, A. Staebler, Nicolas Kersten, A. Koch, Cansu E. Önder, A. Keller, Simone Liebscher, A. Hartkopf, M. Hahn et al. · 2023 · Journal of experimental & clinical cancer research : CR
94. Afatinib as first‐line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature
    Yuequan Shi, Mengzhao Wang · 2018 · Thoracic Cancer
95. An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression
    Debjani Pal, Polona Šafarič Tepeš, Trine Lindsted, Ingrid Ibarra, Amaia Lujambio, Vilma Jiménez Sabinina, Şerif Şentürk, Madison A. Miller, Navya Korimerla, Jiahao Huang et al. · 2021 · eLife
96. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP‐412 (AV‐412) in mouse xenograft models
    Tsuyoshi Suzuki, Akihiro Fujii, Junichi Ohya, Hideo Nakamura, Fumiko Fujita, Masako Koike, Masahide Fujita · 2009 · Cancer Science
97. Estrogen receptor alpha (ESR1)-signaling regulates the expression of the taxane-response biomarker PRP4K
    Sara Lahsaee, Dale Corkery, Livia E. Anthes, Alice C. Holly, Graham Dellaire · 2015 · Experimental Cell Research
98. Estimation and Inference for High Dimensional Generalized Linear Models: A Splitting and Smoothing Approach
    Zhe Fei, Yi Li · 2019 · PubMed
99. Targeted therapies for non-small cell lung cancer
    James F. Spicer, Peter Harper · 2005 · International Journal of Clinical Practice
100. High-Throughput Mutational Analysis of the Human Cancer Genome
     Patrick C Ma, Xiaodong Zhang, Zhenghe Wang · 2006 · Pharmacogenomics